Following anti-TNF withdrawal, eosinophilic disease persisted, prompting compassionate off-label treatment with benralizumab, an interleukin-5 (IL-5) receptor α-antagonist, alongside vedolizumab for CD maintenance. This evidence concerns the gene TNF and eosinophil disorder.